Murine experimental models of amyotrophic lateral sclerosis: an update.

Amyotrophic lateral sclerosis C9ORF72 Cerebrospinal fluid Esclerosis lateral amiotrófica FUS Líquido cefalorraquídeo SOD1 TDP43

Journal

Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590

Informations de publication

Date de publication:
26 Apr 2023
Historique:
received: 10 06 2021
accepted: 08 07 2021
pubmed: 29 4 2023
medline: 29 4 2023
entrez: 28 4 2023
Statut: aheadofprint

Résumé

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease whose aetiology is unknown. It is characterised by upper and lower motor neuron degeneration. Approximately 90% of cases of ALS are sporadic, whereas the other 10% are familial. Regardless of whether the case is familial o sporadic, patients will develop progressive weakness, muscle atrophy with spasticity, and muscle contractures. Life expectancy of these patients is generally 2 to 5 years after diagnosis. In vivo models have helped to clarify the aetiology and pathogenesis of ALS, as well as the mechanisms of the disease. However, as these mechanisms are not yet fully understood, experimental models are essential to the continued study of the pathogenesis of ALS, as well as in the search for possible therapeutic targets. Although 90% of cases are sporadic, most of the models used to study ALS pathogenesis are based on genetic mutations associated with the familial form of the disease; the pathogenesis of sporadic ALS remains unknown. Therefore, it would be critical to establish models based on the sporadic form. This article reviews the main genetic and sporadic experimental models used in the study of this disease, focusing on those that have been developed using rodents.

Identifiants

pubmed: 37116688
pii: S2173-5808(23)00018-4
doi: 10.1016/j.nrleng.2021.07.004
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier España, S.L.U.

Auteurs

L Moreno-Jiménez (L)

Laboratorio de Neurobiología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

M S Benito-Martín (MS)

Laboratorio de Neurobiología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

I Sanclemente-Alamán (I)

Laboratorio de Neurobiología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

J A Matías-Guiu (JA)

Departamento de Neurología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

F Sancho-Bielsa (F)

Departamento de Fisiología, Facultad de Medicina de Ciudad Real, Universidad de Castilla-La Mancha, Ciudad Real, Spain.

A Canales-Aguirre (A)

Unidad Preclínica, CIATEJ-CONACyT, Guadalajara, Mexico.

J C Mateos-Díaz (JC)

Departamento de Biotecnología Industrial, CIATEJ-CONACyT, Zapopan, Mexico.

J Matías-Guiu (J)

Laboratorio de Neurobiología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain; Departamento de Neurología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.

J Aguilar (J)

Laboratorio de Neurofisiología Experimental y Circuitos Neuronales del Hospital Nacional de Parapléjicos, Toledo, Spain.

U Gómez-Pinedo (U)

Laboratorio de Neurobiología, Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. Electronic address: u.gomez.pinedo@gmail.com.

Classifications MeSH